Autism as a whole-body disorder that affects the brain (Research from Dr. Martha Herbert)
In early October, shortly after my son was diagnosed with PDD-NOS, a small one-day conference was held in our area. The conference was called "When the Belly is the Beast" and featured presentations by Dr. Martha Herbert (Assistant Professor of Neurology at Harvard Medical School and Pediatric Neurologist at Mass General Hospital) and Pamela Ferro, RN (President of the Gottschall Autism Center). Dr. Herbert's talk focused on a non-traditional view that autism isn't merely a brain disorder, but a whole body disorder that affects the brain. The remainder of the day focused on the benefits of the Specific Carbohydrate Diet (SCD) for diseases like colitis, Crohn's disease, and many cases of autism.
In many ways, this was my indoctrination to the world of autism research. I had already read a ton of conflicting research theories and been left scratching my head. But when Dr. Herbert talked about autism as the result of many different factors—from genetics to the environment—it started to make sense.
The few criticisms I can find on the web of Dr. Herbert align her with the anti-vaccine groups. I haven't found anything specifically where she blames vaccines for autism, but toxins that have traditionally been in vaccines are just one of the many environmental factors she discusses.
I don't blame vaccines. That said, I'm still extremely nervous about them. Vaccines didn't give our son autism, though. He never received an MMR. In fact, he was under a month old when my wife had her first concerns about his development. There are so many different cases of autism, that the only rational explanation—to me—is that these kids are born with immune deficiencies. Then, the multitude of toxins they'll be exposed to in their lifetime negatively affects them, leading to autism. These can happen before birth, after birth, or after a significant trigger (such as a mercury-laden vaccine).
One of Dr. Herbert's well-known papers is called Autism: A Brain disorder or a disorder that affects the brain?. Here is the summary:
Autism is defined behaviorally, as a syndrome of abnormalities involving language, social reciprocity and hyperfocus or reduced behavioral flexibility. It is clearly heterogeneous, and it can be accompanied by unusual talents as well as by impairments, but its underlying biological and genetic basis is unknown. Autism has been modeled as a brain-based, strongly genetic disorder, but emerging findings and hypotheses support a broader model of the condition as genetically influenced and systemic. These include imaging, neuropathology and psychological evidence of pervasive (and not just specific) brain and phenotypic features; postnatal evolution and chronic persistence of brain, behavior, and tissue changes (e.g. inflammation) and physical illness symptomatology (e.g. gastrointestinal, immune, recurrent infection); overlap with other disorders; and reports of rate increases and improvement or recovery that support a role for modulation of the condition by environmental factors (e.g. exacerbation or triggering by toxins, infectious agents, or other stressors, or improvement by treatment). Modeling autism more broadly encompasses previous work, but also encourages the expansion of research and treatment to include intermediary domains of molecular and cellular mechanisms, as well as chronic tissue, metabolic and somatic changes previously addressed only to a limited degree. The heterogeneous biologies underlying autism may conceivably converge onto the autism profile via multiple mechanisms that all somehow perturb brain connectivity. Studying the interplay between the biology of intermediary mechanisms on the one hand and processing and connectivity abnormalities on the other may illuminate relevant final common pathways and contribute to focusing the search for treatment targets in this biologically and etiologically heterogeneous behavioral syndrome.
You can expect me to write much more about Dr. Herbert's research here.




This commentary in the Genomics Law Report’s ongoing series 
